<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Reports of Biochemistry and Molecular Biology</title>
<title_fa></title_fa>
<short_title>rbmb.net</short_title>
<subject>Basic Sciences</subject>
<web_url>http://rbmb.net</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2322-3480</journal_id_issn>
<journal_id_issn_online>2322-3480</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/rbmb</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1400</year>
	<month>5</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2021</year>
	<month>8</month>
	<day>1</day>
</pubdate>
<volume>10</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Signaling Pathway in the Osmotic Resistance Induced by Angiotensin II AT2 Receptor Activation in Human Erythrocytes</title>
	<subject_fa>زیست شناسی سلولی</subject_fa>
	<subject>Cell Biology</subject>
	<content_type_fa>مقالات اصلی</content_type_fa>
	<content_type>Original Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;&lt;em&gt;Background:&lt;/em&gt;&lt;/strong&gt; Angiotensin&amp;nbsp;II regulates&amp;nbsp;blood&amp;nbsp;volume&amp;nbsp;via&amp;nbsp;AT1 (AT1R)&amp;nbsp;and&amp;nbsp;AT2 (AT2R)&amp;nbsp;receptors.&amp;nbsp;As cell integrity is an important feature of mature erythrocyte, we sought to evaluate,&lt;em&gt; in vitro&lt;/em&gt;, whether Angiotensin II modulates resistance to hemolysis and the signaling pathway&amp;nbsp;involved.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;&lt;em&gt;Methods: &lt;/em&gt;&lt;/strong&gt;Human blood samples were collected and hemolysis assay and angiotensin II signaling pathway profiling in erythrocytes were done.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;&lt;em&gt;Results:&lt;/em&gt;&lt;/strong&gt; Hemolysis assay created a hemolysis curve in presence of Ang II in several concentrations (10&lt;sup&gt;-6 &lt;/sup&gt;M, 10&lt;sup&gt;-8 &lt;/sup&gt;M, 10&lt;sup&gt;-10 &lt;/sup&gt;M, 10&lt;sup&gt;-12 &lt;/sup&gt;M). Angiotensin II demonstrated protective effect, both in osmotic stressed and physiological situations, by reducing hemolysis in NaCl 0.4% and 0.9%. By adding receptors antagonists (losartan, AT1R antagonist and PD 123319, AT2R antagonist) and/or signaling modulators for AMPK, Akt/PI3K, p38 and PKC we showed the protective effect was enhanced with losartan and abolished with PD 123319. Also, we showed activation of PKC as well as PI3K/Akt pathways in this system.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;&lt;em&gt;Conclusions:&lt;/em&gt;&lt;/strong&gt; Briefly, Ang II protects human erythrocytes from hypo-osmotic conditions-induced hemolysis by activating AT2 receptors and triggering both the intracellular pathways.&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Angiotensin II, Erythrocyte, Osmotic fragility, Signaling pathway.</keyword>
	<start_page>314</start_page>
	<end_page>326</end_page>
	<web_url>http://rbmb.net/browse.php?a_code=A-10-713-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Camila Cristina</first_name>
	<middle_name></middle_name>
	<last_name>Guimarães-Nobre</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460012682</code>
	<orcid>100319475328460012682</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Grupo de Pesquisa em Fisiologia Eritróide - GPFisEri, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil &amp; Programa de Pós-graduação em Endocrinologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Brazil.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Evelyn</first_name>
	<middle_name></middle_name>
	<last_name>Mendonça-Reis</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460012683</code>
	<orcid>100319475328460012683</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Grupo de Pesquisa em Fisiologia Eritróide - GPFisEri, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil &amp; Programa de Pós-graduação em Endocrinologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Brazil.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Luana </first_name>
	<middle_name></middle_name>
	<last_name>Passinho-da-Costa</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460012684</code>
	<orcid>100319475328460012684</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Grupo de Pesquisa em Fisiologia Eritróide - GPFisEri, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil &amp; Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Leandro</first_name>
	<middle_name></middle_name>
	<last_name>Miranda-Alves</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460012685</code>
	<orcid>100319475328460012685</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Laboratório de Endocrinologia Experimental- LEEx, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil &amp; Programa de Pós-graduação em Endocrinologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Brazil &amp; Programa de Pós-graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Clemilson</first_name>
	<middle_name></middle_name>
	<last_name>Berto-Junior</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460012686</code>
	<orcid>100319475328460012686</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Grupo de Pesquisa em Fisiologia Eritróide - GPFisEri, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil &amp; Laboratório de Endocrinologia Experimental- LEEx, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil &amp; Programa de Pós-graduação em Endocrinologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Brazil &amp; Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Campus Macaé, Brazil.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
